Trial Profile

A Phase 3 Study of ZSP1273 in Otherwise Healthy Children 2-11 Years Old With Influenza A

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Onradivir (Primary) ; Oseltamivir
Indications Influenza A virus infections
Focus Registrational; Therapeutic Use
Sponsors Guangdong Raynovent Biotech

Most Recent Events

16 Dec 2025 Planned number of patients changed from 114 to 119.
16 Dec 2025 Planned End Date changed from 17 Sep 2026 to 31 Dec 2025.
16 Dec 2025 Planned primary completion date changed from 17 Jun 2026 to 17 Dec 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com